文献速递骨肌MR

T2信号强度作为影像生物标志物用于接受确定性电子束照射的手部(Dupuytren病)和足部(Ledderhose病)浅表纤维瘤病患者

T2 signal intensity as an imaging biomarker for patients with superficial Fibromatoses of the hands (Dupuytren's disease) and feet (Ledderhose disease) undergoing definitive electron beam irradiation.
PubMed 文献 · Skeletal Radiol · 2017-10-30

本研究纳入1例男性和9例女性共37个浅表纤维瘤病病灶,评估标准6 MeV电子束治疗(每次3 Gy,10或12次,分程治疗中间休息3个月)前后MRI表现。治疗后病灶平均体积从1.5 cm³降至1.2 cm³(p=0.01),T2高信号评分从3.0降至2.1(p<0.0001),强化评分从3.8降至3.0(p<0.0001)。结论认为MRI对评估电子束治疗患者有价值,治疗前较高T2信号可能预测放疗获益,T2低信号可能是比体积更好的疗效标志物。

要点

  • 电子束治疗前后MRI显示病灶体积、T2高信号和强化评分均显著下降。
  • 治疗前较高T2信号强度可能预测放疗获益。
  • T2低信号可能是比病灶大小更好的疗效标志物。

核心结论

  • MRI对评估接受电子束治疗的浅表纤维瘤病患者有价值;治疗前较高T2信号强度可能预测放疗获益;T2低信号可能是比病灶大小更好的疗效标志物。

研究设计与样本

  • 研究纳入1例男性和9例女性患者共37个浅表纤维瘤病病灶,平均年龄60.7岁;标准6 MeV电子束治疗每次3 Gy、共10或12次,分程治疗中间休息3个月;由经过专科培训的骨肌放射科医生评估治疗前后MRI的病灶体积(cm³)、T2信号强度和强化(5级有序量表),并与临床复合1-5级有序量表、Karnofsky行为状态量表和患者报告的10分疼痛视觉模拟量表进行相关性分析。

关键影像表现/征象

  • 治疗前后MRI评估病灶体积、T2信号强度和强化。
  • 平均体积从1.5 cm³降至1.2 cm³(p=0.01,配对t检验)。
  • 平均T2高信号评分从3.0降至2.1(p<0.0001,Wilcoxon符号秩检验)。
  • 22个病灶可评估的平均强化评分从3.8降至3.0(p<0.0001,Wilcoxon符号秩检验)。

诊断标准与关键数值

  • T2信号强度和强化采用5级有序量表评估。
  • 临床反应采用复合1-5级有序量表、Karnofsky行为状态量表和患者报告的10分疼痛视觉模拟量表评估。
  • 治疗后T2信号与行为状态和疼痛的相关性弱(Spearman's ρ分别为-0.37和0.16)。

临床应用与阅片要点

  • MRI可用于评估接受电子束治疗的浅表纤维瘤病患者。
  • 治疗前较高T2信号强度可能预测放疗获益。
  • T2低信号可能是比病灶大小更好的疗效标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Electron beam therapy is a definitive radiation treatment option for superficial fibromatoses of the hands and feet. Because objective criteria for treatment response remain poorly defined, we sought to describe changes in electron beam treated lesions on MRI.

MATERIALS AND METHODS: The study included 1 male and 9 female patients with a total of 37 superficial fibromatoses; average age was 60.7 years. Standard 6 MeV electron beam treatment included 3 Gy per fraction for 10 or 12 treatments using split-course with 3-month halfway break. Pre- and post-treatment MRIs were evaluated to determine lesion size (cm3), T2 signal intensity and contrast enhancement (5-point ordinal scales) by a fellowship trained musculoskeletal radiologist. MRI findings were correlated with clinical response using a composite 1-5 ordinal scale, Karnofsky Performance Scale and patient-reported 10-point visual analog scale for pain.

RESULTS: Mean volume decreased from 1.5 to 1.2 cm3 (p = 0.01, paired t-test). Mean T2 hyperintensity score decreased from 3.0 to 2.1 (p < 0.0001, Wilcoxon signed-rank). Mean enhancement score available for 22 lesions decreased from 3.8 to 3.0 (p < 0.0001, Wilcoxon signed-rank). Performance scores improved from 78.9 ± 13.7 to 84.6 ± 6.9 (p = 0.007, paired t-test). Pain scores decreased from 3.0 ± 3.3 to 1.1 ± 2.0 (p = 0.0001, paired t-test). Post-treatment T2 signal correlated weakly with performance and pain (Spearman's ρ = -0.37 and 0.16, respectively).

CONCLUSIONS: MRI is valuable for evaluating patients undergoing electron beam therapy for superficial fibromatoses: higher pretreatment T2 intensity may predict benefit from radiotherapy. T2 hypointensity may be a better marker than size for therapeutic effect.

来源:Skeletal Radiol,查看原文。版权归原作者所有。

引用

  1. Banks JS, Wolfson AH, Subhawong TK, et al. T2 signal intensity as an imaging biomarker for patients with superficial Fibromatoses of the hands (Dupuytren's disease) and feet (Ledderhose disease) undergoing definitive electron beam irradiation. Skeletal Radiol. 2017. PMID: 29085992. doi:10.1007/s00256-017-2792-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。